Highest-materiality recent filing
21 PV patients: 5 phlebotomies during active treatment vs 80 in prior 6 months; only 4 in 16-week follow-up.
Silence Therapeutics enters new ATM with Jefferies; says not PFIC for 2025
Entered at-the-market equity offering agreement with Jefferies LLC; prior 2021 ATM agreement terminated.
Silence Therapeutics FY 2025 net loss $88.6M; top-line divesiran data on-track for Q3 2026
Net loss widened to $88.6M ($0.63/share) from $45.3M ($0.33/share) in FY 2024.
Craig Tooman stepped down as President, CEO and Board member effective Dec 14, 2025 by mutual consent.
Cash and investments $102.2M as of Sept 30, 2025, providing runway into 2028.
48 phlebotomy-dependent PV patients enrolled in global, randomized, double-blind, placebo-controlled study.
Silence Therapeutics Q1 net loss widens to $28.5M; cash runway extended into 2028
Cash and short-term investments $136.5M at Mar 31, 2025, down from $147.3M at Dec 31, 2024.
Silence Therapeutics extends cash runway into 2027; will require partner for zerlasiran Phase 3
Net loss of $45.3M ($0.33 per share) for FY2024, compared to $54.2M loss in FY2023.
On May 5, 2025, upon the recommendation of the Nominations Committee, the Board appointed Tim McInerney to serve as a director of the Company, effective immediately.
On May 5, 2025, James Ede-Golightly notified the board of directors (the “ Board ”) of Silence Therapeutics plc (the “ Company ”) of his decision to retire from the Board following the end of his current term, which expires at the end of the Company’s 2025 Annual General Meeting of Shareholders, which is anticipated to be held on June 26, 2025 (the “ 2025 AGM ”).
Max materiality 0.75 · Median 0.55 · Most common event earnings